Critical analysis of ineffective post implantation implantable cardioverter-defibrillator-testing

AIM To test of the implantable-cardioverter-defibrillator is done at the time of implantation. We investigate if any testing should be performed.METHODS All consecutive patients between January 2006 and December 2008 undergoing implantable cardioverterdefibrillator(ICD) implantation/replacement(a to...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of cardiology Vol. 9; no. 2; pp. 167 - 173
Main Authors Roos, Markus, Geller, J Christoph, Ohlow, Marc-Alexander
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 26.02.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:AIM To test of the implantable-cardioverter-defibrillator is done at the time of implantation. We investigate if any testing should be performed.METHODS All consecutive patients between January 2006 and December 2008 undergoing implantable cardioverterdefibrillator(ICD) implantation/replacement(a total of 634 patients) were included in the retrospective study.RESULTS Sixteen patients(2.5%) were not tested(9 with LA/LVthrombus, 7 due to operator’s decision). Analyzed were 618 patients [76% men, 66.4 + 11 years, 24% secondary prevention(SP), 46% with left ventricular ejection fraction(LVEF) < 20%, 56% had coronary artery disease(CAD)] undergoing defibrillation safety testing(SMT) with an energy of 21 + 2.3 J. In 22/618 patients(3.6%) induced ventricular fibrillation(VF) could not be terminated with maximum energy of the ICD. Six of those(27%) had successful SMT after system modification or shock lead repositioning, 14 patients(64%) received a subcutaneous electrode array. Younger age(P = 0.0003), non-CAD(P = 0.007) and VF as index event for SP(P = 0.05) were associated with a higher incidence of ineffective SMT. LVEF < 20% and incomplete revascularisation in patients with CAD had no impact on SMT.CONCLUSION Defibrillation testing is well-tolerated. An ineffective SMT occurred in 4% and two third of those needed implantation of a subcutaneous electrode array to passa SMT > 10 J.
Bibliography:Markus Roos;J Christoph Geller;Marc-Alexander Ohlow;Heart Center,Salzburger Leite;Zentralklinik Bad Berka,Division of Cardiology,Robert Koch Allee
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Telephone: +49-9771-662602 Fax: +49-9771-65982602
Author contributions: All the authors contributed to the manuscript.
Correspondence to: Markus Roos, MSc, MD, Heart Center, Salzburger Leite, 97616 Bad Neustadt a.d. Saale, Germany. roosmarkus@bluewin.ch
ISSN:1949-8462
1949-8462
DOI:10.4330/wjc.v9.i2.167